All News

Rheumatoid,RA,nodules,damage

Shifting Trends in Initial RA Treatment Approaches

d Caoilfhionn Marie Connolly, MD

A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.

Read Article
RheumNow Podcast square

ACR24 Preview Podcast (11.15.2024)

d Jack Cush, MD

ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.

Read Article
Multimorbidity reduces response to b/tsDMARDs in RA. We can make a difference by treating the whole person! Amazing talk by Dr Iain McInned to wrap up #ACR24 #ReviewCourse. @RheumNow https://t.co/NiaUXzt4nT

Links:

Jiha Lee JihaRheum ( View Tweet)
Biosimilar Slow Growth in USA A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and… https://t.co/yO3tUVk2jj https://t.co/ft6gqpnWMx
Dr. John Cush RheumNow ( View Tweet)
FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/Nq09iEoxJ9 https://t.co/JG4P8zMw9j
Dr. John Cush RheumNow ( View Tweet)
biosimilars2.jpg

Biosimilar Slow Growth in USA

d Jack Cush, MD

A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and autoimmune disorders. The following are takeaway bullets from this informative article.

Read Article
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Dr. Quotes (11.8.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.

Read Article
Weight Loss Drugs and the Loss of Skeletal Muscle Mass A commentary in The Lancet emphasizes the importance of skeletal muscle mass in medically induced weight loss, especially with the use of GLP-1 receptor agonists. While these drugs are effective for obesity treatment, there… https://t.co/8AOgDUajw6 https://t.co/0vntwZSpLy
Dr. John Cush RheumNow ( View Tweet)
Liver.hepatitis.jpg

Advances in the treatment of autoimmune hepatitis

d EurekAlert!

Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure. 

Read Article
In an RCT of colchicine vs PBO in #gout for 6 months shows that colchicine prophylaxis when initiating ULT did not increase the odds of achieving gout remission. https://t.co/kgNzw0UUIq https://t.co/ZdBT0Fp9Gx

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 26 RCTs suggests JAK inhibitors have a low, but signif. increased risk of infections (vs placebo) (RR 1.39; 1.096-1.76). No risk of tuberculosis or hepatitis, but an incr. risk of H. zoster was seen (RR 1.71; 0.84-3.51) https://t.co/kXOcldz46l https://t.co/Y5OWk4W1NZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Iberdomide Efficacy in Cutaneous Lupus berdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).… https://t.co/2LtBDOIBrN https://t.co/giVDgZBiyk
Dr. John Cush RheumNow ( View Tweet)
FDA's perspective on the use of artificial intelligence in drug development. - FDA is committed to a risk-based regulatory framework that promotes innovation & protects Pt safety - Est. CDER AI Council to coordinate, develop, & support internal & external AI-related activities… https://t.co/BLCYmBBJMY https://t.co/fMie3oOfmn
Dr. John Cush RheumNow ( View Tweet)
An 11 yr study of 2187 #RA pts Rx w/ 3068 treatment courses of biologics or JAki, found 275 new cases of #CKD . Compared w/ CTLA4-Ig, TNFi significantly lower CKD rates (HR 0.67), whiile JAKi higher CKD rates (HR 2.16). https://t.co/2Y5BuDzJRs https://t.co/e81lOhOMjX

Links:

Dr. John Cush RheumNow ( View Tweet)
Overview of IL-23 inhibition for chronic inflammatory disease (partial read) from Lancet. Started with targeting the p40 subunit shared between IL-12 & IL-23A. Now we have specific inhibitors of the p19 protein of IL-23A. These agents are superior to TNFi in plaque… https://t.co/ud61WLgWs2 https://t.co/fQ7WhLyrsi
Dr. John Cush RheumNow ( View Tweet)
SGLT2 Inhibitor Protective Effects in Lupus Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D). https://t.co/I5ZrA9pXRU https://t.co/8U0ILPbMuN

Links:

Dr. John Cush RheumNow ( View Tweet)
GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed. https://t.co/Ch5XYlq6lX

Links:

Dr. John Cush RheumNow ( View Tweet)

Are seronegative RA and clinically suspect arthralgia pts represented in randomized clinical trials? Most RCTs (And prevention trials) predominantly enroll seropositive patients. - potentially overlooking seronegative individuals with arthralgia-at-risk. https://t.co/D1eOApgn1p https://t.co/IBCNtNW8uI

Links:

Dr. John Cush RheumNow ( View Tweet)
Cutaneous.lupus.SLE.Face.dermnetnz

Iberdomide Efficacy in Cutaneous Lupus

d Jack Cush, MD

Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.